Amar Sharma PhD joined Retro after completing his doctoral training in Clinical Neurosciences at the Wellcome Trust – MRC Stem Cell Institute at the University of Cambridge, UK. His work focussed on designing an AAV-based gene therapy to rejuvenate aged oligodendrocyte progenitor cells to treat progressive multiple sclerosis, and other degenerative demyelinating diseases. Amar joined Retro to design the world’s first rejuvenation therapy based on partial cellular reprogramming. He is building Retro’s molecular biology, vector production, vector quality control and in vitro capabilities to accelerate our research and discovery. Outside of work, Amar enjoys cooking, rowing, and spending as much time in the California sun as possible. He still contributes to academia by reviewing papers for the American Society of Cell and Gene Therapy’s Molecular Therapy family of scientific journals.